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Abstract: Resting heart rate (rHR) and heart rate variability (HRV) are non-invasive measurements 
that predict the risk of sudden cardiac death (SCD). Marine n-3 polyunsaturated fatty acid (PUFA) 
supplementation may decrease rHR, increase HRV, and reduce the risk of SCD. To date, no studies 
have investigated the effect of marine n-3 PUFA on HRV in renal transplant recipients. In a 
randomized controlled trial, 132 renal transplant recipients were randomized to receive either three 
1 g capsules of marine n-3 PUFA, each containing 460 mg/g EPA and 380 mg/g DHA, or control 
(olive oil) for 44 weeks. HRV was calculated in the time and frequency domains during a 
conventional cardiovascular reflex test (response to standing, deep breathing, and Valsalva 
maneuver) and during 2 min of resting in the supine position. There was no significant effect of 
marine n-3 PUFA supplementation on time-domain HRV compared with controls. rHR decreased 
3.1 bpm (± 13.1) for patients receiving marine n-3 PUFA compared to 0.8 (± 11.0) in controls (p = 
0.28). In the frequency domain HRV analyses, there was a significant change in response to standing 
in both high and low frequency measures, 2.9 (p = 0.04, 95% CI (1.1;8)) and 2.7 (p = 0.04, 95% CI 
(1.1;6.5)), respectively. In conclusion, 44 weeks of supplemental marine n-3 PUFAs in renal 
transplant recipients significantly improved the cardiac autonomic function, assessed by measuring 
HRV during conventional cardiovascular reflex tests.  
Keywords: marine n-3 PUFA; heart rate variability; resting heart rate; renal transplant recipients 
 
1. Introduction 
Sudden cardiac death (SCD) is a major cause of death in patients with chronic kidney disease 
(CKD) [1,2]. Heart rate variability (HRV) and resting heart rate (rHR) are non-invasive measurements 
that may predict SCD risk [3]. HRV can be measured by the beat-to-beat variability in heart rate with 
either time-domain or frequency-domain analyses during passive or controlled active testing. 
Autonomic dysfunction, reflected in an imbalance between sympathetic and parasympathetic 
activity, may increase rHR and decrease HRV [4,5]. Previous studies have shown that patients with 
ischemic heart disease [5], diabetes mellitus [6], and chronic kidney disease (CKD) [4,7–9], with a 
well-documented high risk of SCD, have an attenuated HRV often in combination with a high rHR. 
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After renal transplantation, HRV increases due to improved autonomic function [10,11], but the risk 
of SCD after renal transplantation still remains high [1,12]. 
Fish and seafood are the main sources of marine n-3 polyunsaturated fatty acids (PUFAs), 
including the two major PUFAs, eicosapentaenoic acid (EPA 20:5) and docosahexaenoic acid (DHA 
22:6) [13]. A regular intake of dietary or supplemental marine n-3 PUFA has shown a positive effect 
on autonomic cardiac function, with a decrease in rHR and an increase in HRV in several patient 
groups, suggesting it might protective against SCD [3,14,15]. This effect seems to be dose-dependent 
[16,17], and might translate into a specific threshold level for lowering the risk of all-cause mortality 
and SCD [13,18]. 
Two recent observational studies investigated the relationship between the plasma content of 
marine n-3 PUFA and risk of SCD in renal transplant recipients, showing that high levels of plasma 
marine n-3 PUFA were inversely associated with all-cause mortality and SCD [12,19]. A number of 
small randomized controlled trials have shown that supplementation with marine n-3 PUFA may 
have a beneficial effect on lipids and blood pressure in renal transplant recipients [20], but to date, 
no large intervention studies with cardiovascular endpoints exists. The present study is a sub-study 
of the recently published trial “The effect of Omega-3 Fatty Acids in Renal Transplantation” 
(ORENTRA) [21] and, to our knowledge, was the first study to investigate the effect of marine n-3 
PUFA on HRV and rHR in renal transplant recipients. 
The aim of this study was to examine the effect of high dose marine n-3 PUFA on rHR and time- 
and frequency-domain HRV in renal transplant recipients. 
2. Material and Methods 
2.1. Study Design 
The study was a single-center, randomized, double-blind, controlled, parallel-grouped trial in 
Norwegian renal transplant recipients. Eligible patients were adults aged above 18 and had a 
functional kidney graft with an eGFR > 30 mL/min/1.73 m2 at 6–8 weeks after the renal transplantation 
and provided written informed consent. Exclusion criteria were allergy to the study drug, fish, or 
other seafood, patients receiving a kidney from a donor older than 75 years, participation in other 
clinical trials, and citizenship in a foreign country. 
Patients were randomized to either marine n-3 PUFA (460 mg/g EPA and 380 mg/g DHA 
(Omacor)) given as one capsule of 1 g three times daily, or three capsules of 1 g extra virgin olive oil, 
per day. Omacor and control oil in capsules were both provided by Pronova Biopharma. 
Randomization codes were generated by a computer. Study participants, care providers, and 
investigators were kept blinded during the study period.  
The primary endpoint of the main trial was mGFR and power calculation was based on an 
absolute difference in mGFR of 8.0 mL/min/1.73 m2, which required 132 patients to be enrolled. This 
sub-study investigated a secondary endpoint, which was absolute change in HRV during follow up. 
Post hoc additional analyses were done in a subgroup of patients with baseline plasma marine n-3 
PUFA < 6 wt. %. Further details on study design, participants, and sample size have previously been 
published [21]. 
2.2. Measurements 
Measurements were performed 8-week post-transplant (baseline) and one year after 
transplantation (end of study). HRV and rHR measurements were obtained in the morning, followed 
by blood samples, including aliquots used for fatty acid analysis. Marine n-3 PUFA was defined as 
the sum of EPA and DHA quantified as weight in percentage (wt. %) of total plasma phospholipid 
fatty acid. Gas chromatography was used to determine fatty acid distribution according to standard 
procedures [22]. 
HRV was calculated in time and frequency domain during conventional cardiovascular reflex 
tests (response to standing, deep breathing, and Valsalva maneuver) and during 2 min of resting in 
the supine position. The tests were performed by laboratory technicians using a VagusTM (Medicus 
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Engineering, Aarhus, Denmark) [23]. This device automatically records an ECG signal with a 
sampling frequency of 1000 Hz, from which HR and HRV are deduced and shown on a display. Three 
cardiovascular reflex tests were performed using a standard protocol and recommendations, 
including (1) response to standing, (2) deep breathing, and (3) Valsalva test [24]. The test of response 
to standing is also known as the 30/15 ratio because tests indicate that the shortest R–R interval (time 
between beat in milliseconds) is found around 15th beat and the longest R–R interval is found around 
the 30th beat. The ratio is obtained by continuously measuring R–R intervals from when an individual 
is in a supine position to about a minute after the patient stands up. The 30/15 ratio is largely a 
measure of parasympathetic function. The deep breathing test is a test where the device acts as a 
pacer for the patients breathing. The pace of the breathing is six breaths per minute and the device 
paces the patient through the instructions on the display. During deep inspiration the heart rate 
increases, and during expiration the heart rate decreases. After 60 s of deep breathing exercise, the 
mean ratio of heart rates is calculated. The Valsalva test is a response test where the patient exhales 
with a pressure of 40 mmHg for 15 s. The Valsalva ratio is calculated as the longest and shortest R–R 
intervals during forced expiration in 15 s against a fixed resistance of 40 mmHg and 45 s of normal 
breathing. The Valsalva ratio is a measure of both parasympathetic, sympathetic function, and 
baroreceptor function. Each test was followed by a 1 min break. The cardiovascular reflex tests were 
performed by trained examiners and were preceded by a 30 min period of rest in a supine position 
in a quiet and isolated room. Antiarrhythmic medication, including betablockers, were not taken the 
morning before HRV measures. 
The following HRV matrices were used: In the time domain we used standard deviation of 
normal-to-normal intervals (SDNN). The HRV parameter SDNN is a measure of combined 
sympathetic and parasympathetic activity. In the frequency domain, we used the low-frequency (LF) 
0.04–0.15 Hz and the high-frequency 0.15–0.4 Hz components. The LF components are influenced by 
sympathetic, parasympathetic, and baroreflex sensitivity. The high frequency (HF) band from 0.15–
0.4 Hz is influenced by parasympathetic and the normal breathing rhythm, mainly contributing to 
power with a center frequency around 0.3 Hz [25]. 
2.3. Ethics 
The trial was approved by the Regional Committees for Medical and Health Research Ethics in 
Norway and The Norwegian Medicines Agency. The trial was completed in accordance with the 
Declaration of Helsinki. Clinical. Trials. Gov. identifier NCT 01744067. 
2.4. Statistical Analyses 
Primary statistical analyses were performed on an intention-to-treat (ITT) basis and findings 
reported accordingly to CONSORT guidelines [26]. In addition, a secondary per-protocol (PP) 
analysis was performed. Baseline data, follow-up data, and effect estimates with precisions have all 
been reported accordingly to the guidelines [26]. A GLM model (type: general linear model) was used 
to assess rHR and HRV effect estimates from baseline to follow-up in an unadjusted analysis. This 
type of method is preferred as it takes the potential of unbalanced groups and risk of regression 
towards the mean into consideration [26]. Missing baseline data were median-imputed [27]. Missing 
data at follow-up were assumed missing at random. Imputation models included all baseline 
variables (Table 1). Linear regression was used for continuous variables and logistic regression for 
categorical variables. Frequency domain HRV measures were log-transformed for analysis. The 
primary analysis was based on the imputed data. Complete case analyses (PP) were also included to 
check sensitivity of the main trial findings. Moreover, a subgroup analysis of patients with plasma 
marine n-3 PUFA < 6 wt. % was assessed to evaluate whether the impact of intervention would be 
more evident in patients with a lower baseline plasma marine n-3 PUFA. A two-sided p value < 0.05 
was considered significant. SPSS version 24.0 was used for statistical analyses. 
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Table 1. Baseline characteristics. 
 Marine n-3 Control 
N 66 66 
Age, years 52.8 (13.5) 54 (14.2) 
Male, % 71 77 
Height, cm 175.4 (10.7) 175.5 (9.4) 
Weight, kg 79.3 (14.9) 81.1 (14.9) 
Systolic blood pressure, mmHg 132.2 (13.8) 135.6 (16.6) 
Diastolic blood pressure, mmHg 81.4 (10.6) 82.4 (9.1) 
Comorbidity, % 
Hypertension 78.8 63.3 
Diabetes mellitus 13.6 19.7 
Coronary disease 12.1 12.1 
Antiarrhythmic drug, % 
Beta-blocker 48.4 34.8 
Verapamil 0.0 1.5 
Amiodarone 0.0 1.5 
ESRD treatment, % 
Hemodialysis 40.9 50.0 
Peritoneal dialysis 28.8 18.2 
Preemptive transplantation 29.3 31.8 
Time in renal replacement therapy, months 7 (0–19) 9 (0–22) 
Living donor, % 21.2 27.3 
Marine n-3 PUFA, wt. % 
Baseline 6.4 (2.2) 6.3 (2.1) 
Data are presented as mean (SD), median (25;75 percentile), or proportion (number of patients) as 
appropriate. Abbreviations: ESRD = end stage renal disease. 
3. Results 
Between 15 June 2013 and 15 June 2014, 298 patients received a kidney transplant at 
Rikshospitalet in Norway; 132 were included in the study. Baseline characteristics are presented in 
Table 1. Complete baseline data have previously been published [21]. During the study, plasma levels 
of marine n-3 PUFA increased significantly in the intervention group, compared to no change in the 
control group, as previously published [21]. 
3.1. Time and Frequency Domain HRV 
The HRV measurements at baseline and follow up are presented in Table 2. Four patients had 
documented arrhythmia at baseline. Time-domain HRV data were comparable in the two groups at 
baseline, and HRV increased slightly in both groups during the study period (Table 2). There was a 
decrease in rHR in the marine n-3 PUFA group of 3.1 bpm (± 13.1), compared to 0.8 (±11.0) in the 
control group (Table 2). Both groups had an increase in SDNN, 7.8 (± 23.3) in the marine n-3 PUFA 
group compared to 3.4 (± 21.8) in the control group. No difference between groups was found in heart 
rate response to the active tests; orthostatic, E:I, or Valsalva. In frequency-domain HRV, the 
orthostatic ratio analysis was significantly different at baseline. The control group had a significantly 
higher level of both low and high frequency HRV, 28.1 and 7.1, compared to 14.6 and 3.0 in the marine 
n-3 PUFA group. 
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Table 2. Time and frequency domain heart rate variability (HRV) at baseline and at end of study. 
 
Marine n-3 (N = 66) Control (N = 66) 
Baseline Follow up Baseline Follow up 
TIME DOMAIN 
Resting heart rate, bpm 74.4 (12.6) 71.3 (14.3) 73.0 (10.6) 72.2 (12.0) 
SDNN, ms2 31.6 (22.6) 39.2 (30.1) 34.0 (24.3) 37.4 (25.3) 
Orthostatic ratio 1.1 (1.0–1.1) 1.1 (1.0–1.1) 1.1 (1.0–1.2) 1.1 (1.0–1.2) 
E:I ratio 1.1 (1.1–1.3) 1.1 (1.1–1.2) 1.2 (1.1–1.3) 1.2 (1.1–1.4) 
Valsalva ratio 1.4 (1.3–1.7) 1.4 (1.2–1.6) 1.4 (1.3–1.6) 1.52 (1.3–1.8) 
FREQUENCY DOMAIN 
Orthostatic, ms2 
LF 14.6 (4.3–35.6) 20.9 (8.7–62.0) 28.1 * (10.0–99.0) 27.5 (8.0–86.0) 
HF 3.0 (0.9–9.0) 6 (0.9–21.6) 7.1 * (1.9–25.1) 6.7 (3.6–18.7) 
E:I, ms2 
LF 406.5 (165.5–1259.2) 437.0 (132.2–1302.4) 845.5 (133.3–1915.0) 962.8 (233.6–2018.3) 
HF 82.0 (13.5–392.6) 70.3 (22.4–403.4) 125.2 (24.9–428.0) 153.1 (36.7–410.0) 
Valsalva, ms2 
LF 196 (74.4–1063.1) 302.8 (119.9–1063.1) 367.2 (59.0–1192.0) 289.4 (107.4–1743.0) 
HF 27.9 (8.5–114.9) 50.3 (20.7–150.3) 50.5 (15.1–158.3) 62.8 (11.5–262.0) 
Data are presented as mean (SD) or median (25–75 percentile) as appropriate. Abbreviations: bpm = 
beats per minute. SDNN = standard deviation of normal-to-normal intervals. E:I = 
expiratory:inspiratory. LF = low frequency. HF = high frequency. * Significant difference (p < 0.05) 
from marine n-3 PUFA. 
The intervention effects of marine n-3 PUFA compared to the control group for both ITT (n = 
132) and PP (n = 102) population analyses are presented in Table 3. There were no significant 
differences between groups in rHR or SDNN during supine resting. In the time domain, Valsalva 
ratio was the only parameter with a significant reduction of 0.1 ms2 (p = 0.04, 95% CI (−0.2; −0.01)) in 
the ITT population. In the PP population, the orthostatic test increased significantly by 0.2 ms2 (p = 
0.04, 95% CI (0.01; 0.4)) in the marine n-3 PUFA group compared to the control group. In the 
frequency domain, the intervention effect was significant in the orthostatic test in both low and high 
frequency in the ITT and PP population. The effect of marine n-3 PUFA was 2.9 (p = 0.04, 95% CI (1.1; 
8)) and 2.7 (p = 0.04, 95% CI (1.1; 6.5)) for respectively HF and LF domains in the ITT population. 
There was no significant effect in E:I test or Valsalva test between groups. 
3.2. Subgroup Analysis 
Subgroup analysis was performed in the 63 patients with plasma marine n-3 PUFA < 6 wt. %. In 
the marine n-3 PUFA group, there was a mean reduction in rHR of 5.0 ± 2.8 bpm, but this was still 
not significant when compared to the control group (data not shown). No significant differences were 
found between the two groups in the time-domain or frequency-domain HRV (data not shown). 
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Table 3. Intervention effect estimates (95% confidence interval) for the ITT and PP population. 
 N 
Intervention 
Effect Estimate 
95% Confidence 
Interval 
p Value 
TIME DOMAIN 
Resting heart rate (bpm) 
ITT 132 −2.7 (−7.5;2.1) 0.28 
PP 102 −3.4 (−8.7;1.2) 0.22 
SDNN (ms) 
ITT 132 1.9 (−7.3;11.1) 0.69 
PP 102 −1.8 (−12.0;8.4) 0.73 
Orthostatic (ratio) 
ITT 132 0.1  (−0.02;0.2) 0.1 
PP 102 0.2  (0.01;0.4) 0.04 
E:I (ratio) 
ITT 132 −0.01  (0.06;0.05) 0.86 
PP 102 −0.01  (−0.07;0.06) 0.85 
Valsalva (ratio) 
ITT 132 −0.1  (−0.2;−0.01) 0.04 
PP 102 −0.05 (−0.2;0.07) 0.41 
FREQUENCY DOMAIN 
Orthostatic test (ms2) 
HF 
ITT 132 2.9 (1.1;8.0) 0.04 
PP 102 3.7 (1.2;11.2) 0.02 
LF 
ITT 132 2.7  (1.1;6.5) 0.04 
PP 102 3.3 (1.1;9.6) 0.03 
E:I test (ms2) 
HF 
ITT 132 0.7 (0.2;2.1) 0.53 
PP 102 0.5 (0.2;2.0) 0.38 
LF 
ITT 132 0.5 (0.2;1.2) 0.12 
PP 102 0.4 (0.2;1.2) 0.13 
Valsalva test (ms2) 
HF 
ITT 132 1.1 (0.5;2.5) 0.85 
PP 102 0.9 (0.4;2.2) 0.82 
LF 
ITT 132 1.2 (0.5;2.6) 0.7 
PP 102 1.1 (0.4;2.6) 0.87 
Abbreviations: ITT = intention-to-treat population. PP = per-protocol population. 
4. Discussion 
The main findings of this study were that high doses of marine n-3 PUFA supplementation in 
renal transplant recipients for 44 weeks significantly improved frequency-domain HRV in response 
to standing, but did not affect time-domain HRV or rHR. 
Previous studies have shown improvement in HRV in end-stage kidney disease patients after 
receiving a renal transplant [10]. Cashion et al. conducted a study of 90 kidney- and 30 kidney-
pancreas transplant recipients, where patients without diabetes receiving a kidney transplant had an 
improvement in HRV after 6 months, as did patients with diabetes receiving a kidney-pancreas 
transplant after 12 months [11]. This was confirmed in a study investigating 24 h time- and frequency-
domain HRV prior to and at 6 months after kidney and kidney–pancreas transplantation, with an 
increase in HRV in all 57 patients [28]. Our results showed an increase in HRV in both groups in the 
study period from baseline, which was 8-week post-transplant, to 44-week post-transplant, with an 
additional improvement from intervention on frequency domain parameters (response to standing). 
Thus, it seems that renal transplantation improves autonomic function and HRV per se, and our data 
suggest that marine n-3 PUFA supplementation might have a further beneficial effect on autonomic 
function in this setting. 
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However, only the frequency-domain HRV in response to standing was significantly improved 
after supplementation with marine n-3 PUFA. The orthostatic test is the result of a transient decrease 
in blood pressure and increase in the HR following translocation of blood due to active standing from 
the supine position. Failure to increase HRV component LF on standing reflects an impaired 
sympathetic response or depressed baroreflex sensitivity [29,30]. In addition, HRV in response to 
standing might be more precise in patients with severe autonomic neuropathy, with a better HRV 
amplitude, making it possible to differentiate between an actual signal and background noise [25]. 
On the other hand, frequency-domain analyses may be distorted by verbal activity and respiratory 
changes, making the results less reliable [31].  
In general, studies of the effect of marine n-3 PUFA on HRV have shown diverging results. A 
meta-analysis from 2013, including studies of patients with different co-morbidities, concluded that 
there was an overall effect on HRV only on parameters reflecting an increased vagal tone (frequency 
domain) [32]. To our knowledge, no previous studies have examined the effect of marine n-3 PUFA 
consumption on HRV in renal transplant recipients, and only a few studies exist in patients with 
CKD. Previously, two small RCTs in HD patients did not find an effect of supplementation with 
marine n-3 PUFA on HRV. [8,33]. In the largest study to date, Rantanen et al. randomized 112 HD 
patients to 2 g of marine n-3 PUFA or control for 12 weeks and showed an improvement in HRV 
parameters reflecting vagal tone and a significant reduction in rHR, but no significant effect on the 
primary endpoint, SDNN [34]. There are, however, multiple factors that may affect HRV in patients 
with CKD, including frequent use of medications. In our study, approximately 40% of the patients 
were treated with anti-arrhythmic medication, which may have affected the results. 
In our study, baseline levels of marine n-3 PUFA were relatively high. The Norwegian 
population in general has a documented high average intake of fish, equivalent to 2–3 meals per week 
[35], and concordantly plasma marine n-3 PUFA levels in the Norwegian population are high 
compared to levels of marine n-3 PUFA in other populations [36]. Previous data in Norwegian renal 
transplant recipients [12], and high baseline levels over 6 wt. % in the present study, confirm this.  
It has previously been suggested that specific threshold levels might exist for the protective 
effects of marine n-3 PUFA, based on pooled data from epidemiological studies showing an inverse 
association with a moderate intake (two servings/week) and all-cause mortality [13]. The risk for all-
cause mortality was not lower with an intake above two servings per week, suggesting a possible 
threshold effect. Recent meta-analysis of RCTs also confirmed a dose–response relationship [37]. 
Additionally, different effects of marine n-3 PUFA have different threshold levels. The anti-
arrhythmic and antihypertensive effect may be reached with typical dietary doses [18,38], whereas 
achieving, for example, a triglyceride-lowering effect would require high-dose supplementation [39]. 
Finally, previous data also suggest that dietary consumption or supplementation with marine 
n-3 PUFA may be most effective for risk reduction in populations with low baseline levels [40]. An 
omega-3 index has also been used as a biomarker to predict risk of cardiovascular (CV) death [41]. 
This index defines low levels as <4 wt. % and high levels as >8 wt. %, corresponding to high vs. a low 
risk for CV death. We performed an additional subgroup analysis of patients with a baseline level of 
marine n-3 PUFA below 6 wt. %, which did not alter the results. As the mean dietary intake of marine 
n-3 PUFA in our study was high, very few patients had levels below the suggested threshold level of 
4%. The small sample size of our study did not allow us to explore this further.  
In a large cross-sectional study of 5096 men and women, dietary intake of fish was associated 
with lower rHR [42]. In line with other data, their results also supported a threshold effect from 
marine n-3 PUFA at a dietary consumption of approximately 300 mg/day. In renal transplant 
recipients, one large cross-sectional study showed that a high level of marine n-3 PUFA was 
associated with lower rHR 10 weeks after transplantation [43]. A previous meta-analysis of marine 
n-3 PUFAs’ effect on rHR in randomized trials found that marine n-3 PUFA decreased rHR by 1.6 
bpm, and by 2.5 bpm in trials with baseline rHR above 69 [44]. Another meta-analysis showed a 
significantly reduced rHR after supplementation with marine n-3 PUFA, with a mean reduction of 
2.2 bpm overall and a more pronounced effect from DHA than EPA [45]. In a recent RCT of patients 
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treated with chronic HD, a similar reduction in rHR (2.5 bpm) was shown after treatment with 2 g of 
marine n-3 PUFA for 12 weeks [34].  
In our study, the patients had a relatively high mean rHR at baseline, 74.4 bpm in the marine n-
3 PUFA group and 73.0 bpm in the control group, with a reduction in rHR in both groups during the 
study period. Although our results showed a larger reduction in rHR in marine n-3 PUFA compared 
with controls (3.1 vs. 0.8 bpm), in line with previous studies, the difference was not significant. As 
previous data regarding marine n-3 PUFA and rHR are relatively consistent, our results might have 
been due to the small sample size of our study.  
Two recent observational studies in renal transplant recipients have shown that high levels of 
marine n-3 PUFA are associated with better patient survival [12,19]. In a large cohort study, Eide et 
al. followed 1990 Norwegian renal transplant recipients for a median of 7 years and found that high 
levels of marine n-3 PUFA at baseline were independently associated with lower risk of all-cause 
mortality, and in particular a lower risk of SCD [12]. Using the lowest quartile of marine n-3 PUFA 
as a reference, the hazard ratio for SCD in the highest quartile was 0.08 (95% CI 0.02–0.35). Neto et al. 
showed similar results in an observational study with 627 renal transplant recipients [19], with a 
lower risk of all-cause and cardiovascular mortality in patients with high levels of marine n-3 PUFA. 
These studies are in line with epidemiological data both from the general population [13], and 
patients with CKD [46,47].  
As for data from intervention studies, there has been ongoing controversy regarding the effect 
of marine n-3 PUFA on CV events and death from cardiac causes. However, in recent years, several 
new studies have been published, and the conclusion from two updated meta-analyses was that 
supplementation with marine n-3 PUFA reduces both CV events and CV death [37,48]. In patients 
with CKD, one previous RCT in patients treated with HD showed that supplementation with 1.7 g of 
marine n-3 PUFA significantly reduced the number of myocardial infarctions with no effect on all-
cause mortality [49]. In renal transplant recipients, no intervention studies with marine n-3 PUFA on 
cardiovascular endpoints exist. However, such a study would be warranted considering the low 
levels of marine n-3 PUFA in patients with CKD in general, the high risk of CV events, including 
SCD, and recent epidemiological data in renal transplant recipients. In our study of rHR and HRV as 
surrogate markers for SCD, the results might have been affected by a high background intake of 
marine n-3 PUFA above a certain threshold level, and baseline levels should be taken into 
consideration when planning further studies.  
Strengths and Limitations 
A strength of this study was the study design and the plasma measurements of marine n-3 PUFA 
for evaluation of adherence to the study drug. Another strength was the study duration, which was 
longer than most studies investigating the effect of marine n-3 PUFA on HRV. A limitation was the 
relatively small sample size, which limited the possibility of further subgroup analysis. Furthermore, 
this study only analyzed short-term HRV. Measurements of 24 h HRV include nighttime HRV, which 
is preferable for assessing marine n-3 PUFAs’ effect on vagal tone. Almost half of the study 
population were on antiarrhythmic drugs and, although these medications were not taken before 
HRV measurements, we cannot rule out that they may have affected the results. 
5. Conclusions 
In renal transplant recipients, n-3 PUFA supplementation significantly improved frequency-
domain HRV in response to standing, but did not improve time-domain HRV or rHR. As our results 
were contradictory, additional intervention studies would be needed to clarify the effects of marine 
n-3 PUFA on HRV and possible impact on cardiovascular risk in renal transplant recipients. Such 
studies should be larger with a longer duration, and include hard-end-points and patients with a low 
baseline intake of marine n-3 PUFA.  
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